Nxera Pharma Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Nxera Pharma Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Nxera Pharma Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Nxera Pharma Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
View up-to-date information on Nxera Pharma Co Ltd patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| US11834407B2 | Grant | Substituted cyclohexanes as muscarinic m1 receptor and/or m4 receptor agonists | C07D207/14; C07D209/96; C07D213/57; C07D243/08; C07D271/06; C07D295/205; C07D401/08; C07D403/04; C07D409/08; C07D413/04; C07D413/12; C07D413/14; C07D471/04; C07D471/10; C07D487/04; C07D487/10 | December 05, 2023 |
| US20230382950A1 | Application | Cyclic apelin receptor agonists | A61K47/545; C07K7/08 | November 30, 2023 |
| US20230382949A1 | Application | Linear apelin receptor agonists | A61K38/00; A61K47/60; C07K7/08 | November 30, 2023 |
| AU2022260824A1 | Application | Gpr35 agonist compounds | A61P1/00; A61P29/00; A61P35/00; A61P37/08; A61P9/00; A61P9/12; C07D257/04 | November 09, 2023 |
| AU2022247287A1 | Application | Sars-cov-2 mpro inhibitor compounds | A61P31/14; C07D209/52; C07D403/12; C07D405/06 | November 09, 2023 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer